Leukocyte Interferon-alpha in the Treatment of Chronic Hepatitis C in Finland

References

• References
   Google Scholar
• Finter NB. The naming of cats—and alpha-interferons. Lancet 1996;348:348–9.
   PubMed Web of Science ®Google Scholar
• Viscomi GC, Grimaldi M, Palazzini E, Silvestri S. Human leukocyte interferon alpha: structure, pharmacology, and therapeutic applications. Med Res Rev 1995;15:445–78.
   PubMedGoogle Scholar
• Gattoni A, Romano C, Cecere A, Caiazzo R, Grima P, Altucci P. Efficacy of human leukocyte interferon-α treatment in elderly patients with hepatitis-C virus-related chronic liver disease. Arch Gerontol Geriatr 1996;Suppl 5:305–12.
   Google Scholar
• Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson G, et al. Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial. Hepatology 1997;25:445–8.
   PubMedGoogle Scholar
• Morisco F, Tuccillo C, Iasevoli P, Sessa G, Brunasso G, Caporaso N. Chronic hepatitis C long-term responders to human leukocyte interferon-α therapy: persistence of a sustained biochemical and virological response during 5 years of surveillance. Eur J Gastroenterol Hepatol 1998;10:399–403.
   PubMedGoogle Scholar
• Cantell K, Hirvonen S, Kauppinen HL, Myllylä G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 1981;78:29–38.
   Google Scholar
• Cantell K, Hirvonen S, Koistinen V. Partial purification of human leukocyte interferon on a large scale. Methods Enzymol 1981;78:499–505.
   PubMedGoogle Scholar
• Nyman TA, Tölö H, Parkkinen J, Kalkkinen N. Identification of nine interferon-α subtypes produced by Sendai virus-induced human peripheral blood leucocytes. Biochem J 1998;329:295–302.
   PubMed Web of Science ®Google Scholar
• Pohjanpelto P, Lappalainen M, Widell A, Asikainen K, Paunio M. Hepatitis C genotypes in Finland determined by RFLP. Clin Diagn Virol 1996;7:7–16.
   PubMedGoogle Scholar
• Rönnblom IE, Tiensuu JE, Perers A, Öberg KE, Alm GV. Characterization of anti-interferon-α antibodies appearing during recombinant interferon-α2a treatment. Clin Exp Immunol 1992;89: 330–5.
   Google Scholar
• Öberg K, Alm GV. Development of neutralizing interferon antibodies after treatment with recombinant interferon-α2b in patients with malignant carcinoid tumors. J Interferon Res 1989;9 Suppl 1:S45–9.
   Google Scholar
• Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26 Suppl 1:112S–21S.
   Google Scholar
• Ebeling F, Naukkarinen R, Hanhela J, Jalonen J, Kaukinen L, Salmenperä M, et al. Post-transfusion hepatitis after open-heart surgery in Finland—a prospective study. Transfus Med 1991; 1:103–8.
   Google Scholar
• Pohjanpelto P. Risk factors connected with hepatitis C infections in Finland. Scand J Infect Dis 1992;24:251–2.
   PubMed Web of Science ®Google Scholar
• Berg T, Hopf U, Stark K, Baumgarten R, Lobeck H, Schreier E. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J Hepatol 1997;26:484–91.
   PubMed Web of Science ®Google Scholar
• McCaw R, Moaven L, Locarnini SA, Bowden DS. Hepatitis C virus genotypes in Australia. J Viral Hepat 1997;4:351–7.
   PubMed Web of Science ®Google Scholar
• Roffi L, Ricci A, Ogliari C, Scalori A, Minola E, Colloredo G, et al. HCV genotypes in northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998; 29:701–6.
   PubMed Web of Science ®Google Scholar
• Weiland O, Chen M, Lindh G, Mattsson L, Schvarz R, Sönnerborg A, et al. Efficacy of human leucocyte alphainterferon treatment for chronic hepatitis C virus infection. Scand J Infect Dis 1995;27:319–24.
   Google Scholar
• Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, et al. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996;24:1366–70.
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493–9.
   PubMed Web of Science ®Google Scholar
• Farrell GC, Bacon B, Goldin RD, the Clinical Advisory Group for the Hepatitis C Comparative Study. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Hepatology 1998;27: 1121–7.
   Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485–92.
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon (2b plus ribavirin for 48 weeks or for 24 weeks versus interferon (2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426–32.
   PubMed Web of Science ®Google Scholar
• DiPaola M, Smith T, Ogin E, Marcotte J, Ferencz-Biro K, Liao MJ, et al. Human leukocytes from healthy individuals produce interferons-α8b, α10a and α17b when stimulated with Sendai virus. J Interferon Res 1994;14 Suppl 1:S72.
   Google Scholar
• Foster GR, Rodrigues O, Ghouze F, Schulte-Frohlinde E, Testa
   Google Scholar
• D, Liao MJ, et al. Different relative activities of human cell-derived interferon-α subtypes: IFN-α8 has very high antiviral potency. J Interferon Cytokine Res 1996;16:1027–33.
   PubMedGoogle Scholar
• Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778–89.
   PubMed Web of Science ®Google Scholar
• Terrault N, Feinman SV. Interferons for viral hepatitis. Transfus Med Rev 1995;9:29–52.
   PubMedGoogle Scholar